Phase 2 N=70 Pharmacokinetics and Tolerability Study of Risperidone ISM® in Schizophrenia
Schizophrenia
Primary: Peak Plasma Concentration (Cmax) for Active Moiety — 39.6; 54.1; 53.2; 61.0 ng/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=34 Busulfan/Clofarabine + Allogeneic Stem Cell Transplantation
Acute Myeloid Leukemia · Acute Lymphoblastic Leukemia · Myelodysplastic Syndrome
Primary: Assessment of Donor Stem Cell Engraftment: ANC Count — 33; 0 Participants
Phase 2 N=180 Trial of High-Dose Rifampin in Patients With TB
Tuberculosis
Primary: Steady State Pharmacokinetic Exposure of RIF — 115.6988; 201.9725; 284.4278 Ratio
N/A N=42 Statin Therapy Versus Placebo Prior to Prostatectomy
Cancer · Prostate Cancer
Primary: Measure the Effect of Pre-operative Simvastatin Versus Placebo on the Mevalonate Pathway Synthesis and Target Activation in Benign and Malignant Prostate Tissue…
Phase 2 N=35 Perioperative Therapy for Resectable Pancreatic Cancer
Adenocarcinoma of the Pancreas · Stage IA Pancreatic Cancer · Stage IB Pancreatic Cancer
Primary: Median Overall Survival of Patients With Adenocarcinoma of the Pancreas — 31.6 months
Phase 2 N=34 Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL
Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma
Primary: Progression Free Survival — 18.3 months
Phase 2 N=110 Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma
Adult Anaplastic Astrocytoma · Adult Anaplastic Oligodendroglioma · Adult Giant Cell Glioblastoma
Primary: Number of Dose Limiting Toxicity (DLT) Each Dose Level Phase I — 1; 0; 0; 0 dose limiting toxicities
N/A N=103 Effect of Valacyclovir in the Reduction of HSV-2 Recurrence and Shedding
HIV · HIV Infections
Primary: Herpes Simplex Virus Type 2 Recurrence — 0; 0 Recurrence
N/A N=28 Clinical and Laboratory Study of Lysozyme Deposition on Daily Disposable Contact Lenses
Visual Acuity
Primary: Total Protein and Total Lysosome Deposits — 294.58; 1.68; 244.00; 0.93 (ug/lens)
Phase 2 N=131 A Phase 2a Study Evaluating the Safety and Efficacy of ABT-981 in Patients With Erosive Hand Osteoarthritis
Erosive Hand Osteoarthritis
Primary: Australian/Canadian Hand Osteoarthritis Index (AUSCAN NR3.1) Pain Subdomain Score: Change From Baseline to Week 16 — -10.74; -9.22 units on a scale — p=0.386
Phase 2 N=126 MDCO-216 Infusions Leading to Changes in Atherosclerosis: A Novel Therapy in Development to Improve Cardiovascular Outcomes - Proof of Concept Intravascular Ultrasound (IVUS), Lipids, and Other Surrogate Biomarkers Trial
Acute Coronary Syndrome
Primary: Change From Baseline In Percent Atheroma Volume (PAV) At Day 36 — -0.21; -0.94 change in percent — p=0.0738
N/A N=350 Early Palliative Care in Advanced Lung and Gastrointestinal Malignancies
Non-small Cell Lung Cancer · Small Cell Lung Cancer · Mesothelioma
Primary: Functional Assessment of Cancer Therapy (Quality of Life Measure) — 81.10; 77.70 units on a scale
Phase 2 N=30 Study of Diclofenac Capsules to Treat Pain Following Surgery in Children Ages 6 to <17 Years of Age
Pain, Postoperative
Primary: Plasma Concentration of Diclofenac — 29647.9; 35131.0 mL/hr
N/A N=86 Cleancision IntRaoperative Contamination prEvention Study
Wound Contamination · Colorectal Surgery
Primary: Efficacy (Enteric Bacterial Contamination on the Exposed Surface of the CleanCision Sheath Compared to the Protected Incision Edge) — 33.3; 9.5 % of participants with…
N/A N=136 A Study to Evaluate Tocilizumab Treatment in a Real-Life Setting
Rheumatoid Arthritis
Primary: Percentage of Participants on TCZ Treatment at Month 6 — 86.5 percentage of participants